# Prescription Drug User Fee Act Waivers for Fixed-Combination Antiretroviral Drugs for the President’s Emergency Plan for AIDS Relief: Draft Guidance for Industry - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/prescription-drug-user-fee-act-waivers-for-fixed-combination-antiretroviral-drugs-for-the-presidents-emergency-plan-for-aids-relief-draft-guidance-for-industry/9c15c557-6fcc-4a2d-a6ed-54dc154f114a

> FDA guidance document: Prescription Drug User Fee Act Waivers for Fixed-Combination Antiretroviral Drugs for the President’s Emergency Plan for AIDS Relief: Draft Guidance for Industry. Issue date: June 07, 2018. Get complete insights and analysis.

---

## Details

- Title: Prescription Drug User Fee Act Waivers for Fixed-Combination Antiretroviral Drugs for the President’s Emergency Plan for AIDS Relief: Draft Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2018-06-07
- Comment Close Date: 2018-08-06
- Last Changed: 2020-04-14
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2018-D-1635">FDA-2018-D-1635</a>

## Related Documents

- [Establishing Impurity Specifications for Antibiotics](https://www.globalkeysolutions.net/guidances/guidance-document/establishing-impurity-specifications-for-antibiotics/5bb8badb-7c32-4b76-bfc9-bbb8ab55fb84)
- [PDUFA Waivers, Reductions, and Refunds for Fixed- Combinations and Single-Entity Versions of Previously Approved Antiretrovirals under PEPFAR](https://www.globalkeysolutions.net/guidances/guidance-document/pdufa-waivers-reductions-and-refunds-for-fixed-combinations-and-single-entity-versions-of-previously-approved-antiretrovirals-under-pepfar/6d0b93d6-4d11-41b1-815d-d6970112dcdd)
- [Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA: Draft Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/comparative-analyses-and-related-comparative-use-human-factors-studies-for-a-drug-device-combination-product-submitted-in-an-anda-draft-guidance-for-industry/c8e96dc7-4f82-494f-ae7f-c75cb0d5808d)